Table 3.

The prevalence of liver fibrosis using APRI and Fib-4 score at baseline and at the subsequent annual evaluations corresponding to 36 months, 48 months, and 60 months in all patients and separately for individuals with HIV monoinfection, HIV-HBV co-infection with positive HBsAg and individuals with HIV-HBV and HBsAg loss.

Patient group	Liver fibrosis prevalence
	Baseline	Yearly assessment	Yearly assessment	Yearly assessment
		for 36 months	for 48 months	for 60 months
All patients (n = 212)
APRI >0.5 (%)	23 (10.8%)	27 (12.7%)	19 (9%)	24 (11.3%)
Fib-4 ≥1.45 (%)	21 (9.9%)	19 (9%)	20 (9.4%)	23 (10.8%)
HIV mono-infection (n = 111)
APRI >0.5 (%)	6 (5.4%)	6 (5.4%)	4 (3.6%)	9 (8.1%)
Fib-4 ≥1.45 (%)	8 (7.2%)	8 (7.2%)	8 (7.2%)	10 (9%)
HIV-HBV co-infection with positive HBsAg (n = 62)
APRI >0.5 (%)	14 (22.6%)	13 (21%)	9 (14.5%)	10 (16.1%)
Fib-4 ≥1.45 (%)	10 (16.1%)	6 (9.7%)	7 (11.3%)	8 (12.9%)
HIV-HBV co-infection with HBsAg loss (n = 39)
APRI >0.5 (%)	3 (7.7%)	8 (20.5%)	6 (15.4%)	5 (12.8%)
Fib-4 ≥1.45 (%)	3 (7.7%)	5 (12.8%)	5 (12.8%)	5 (12.8%)